QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:TARS

Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

$31.54
+1.41 (+4.68%)
(As of 02/22/2024 ET)
Today's Range
$29.91
$31.82
50-Day Range
$18.98
$31.55
52-Week Range
$11.33
$31.84
Volume
830,871 shs
Average Volume
735,557 shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.20

Tarsus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
37.0% Upside
$43.20 Price Target
Short Interest
Bearish
16.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Tarsus Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.29 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.88) to ($4.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.07 out of 5 stars

Medical Sector

586th out of 934 stocks

Biological Products, Except Diagnostic Industry

100th out of 160 stocks


TARS stock logo

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

TARS Stock Price History

TARS Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Tarsus Pharmaceuticals Inc.
We Could Be Less Than 3 Months Out from an AI Superevent
According to one of the world’s top AI scientists, there’s a major event coming as soon as three months from today that could cause expensive tech stocks like Microsoft, Google, and NVIDIA to double or triple in price in the months ahead… but whatever you do, don’t go all in on big tech before you have all the details.
TARS Mar 2024 25.000 put
TARS Mar 2024 40.000 call
Biotech High-Flyers That Just Hit 52-Week Highs
CYTK Feb 2024 80.500 call
TARS Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals Inc Ordinary Shares
See More Headlines
Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/22/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TARS
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.20
High Stock Price Target
$54.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+37.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-62,090,000.00
Pretax Margin
-748.73%

Debt

Sales & Book Value

Annual Sales
$25.82 million
Book Value
$7.23 per share

Miscellaneous

Free Float
29,285,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
0.93
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Bobak R. Azamian M.D.
    Co-Founder, President, CEO & Chairman
  • Dr. Bryan Wahl J.D. (Age 46)
    M.D., General Counsel & Corporate Secretary
    Comp: $619.09k
  • Dr. Elizabeth Yeu Lin M.D. (Age 46)
    Chief Medical Advisor & Director
    Comp: $286k
  • Mr. Jeffrey S. Farrow (Age 62)
    CFO & Chief Strategy Officer
  • Dr. Seshadri Neervannan Ph.D. (Age 56)
    Chief Operating Officer
    Comp: $486.67k
  • Mr. David Nakasone
    Head of Investor Relations
  • Ms. Adrienne Kemp
    Senior Director of Corporate Communications
  • Mr. Matthew Rossen M.B.A. (Age 46)
    Vice President of Marketing
  • Mr. Scott Youmans
    Vice President of Sales
  • Ms. Dianne C. Whitfield M.S.W. (Age 47)
    Chief Human Resources Officer
    Comp: $578.9k














TARS Stock Analysis - Frequently Asked Questions

Should I buy or sell Tarsus Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TARS shares.
View TARS analyst ratings
or view top-rated stocks.

What is Tarsus Pharmaceuticals' stock price target for 2024?

5 brokers have issued 12 month price objectives for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $19.00 to $54.00. On average, they anticipate the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for TARS
or view top-rated stocks among Wall Street analysts.

How have TARS shares performed in 2024?

Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of the year. Since then, TARS stock has increased by 55.8% and is now trading at $31.54.
View the best growth stocks for 2024 here
.

Are investors shorting Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 5,430,000 shares, an increase of 8.2% from the January 15th total of 5,020,000 shares. Based on an average daily volume of 705,400 shares, the days-to-cover ratio is presently 7.7 days.
View Tarsus Pharmaceuticals' Short Interest
.

When is Tarsus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our TARS earnings forecast
.

How can I listen to Tarsus Pharmaceuticals' earnings call?

Tarsus Pharmaceuticals will be holding an earnings conference call on Tuesday, February 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.34. The firm earned $1.24 million during the quarter, compared to analyst estimates of $1 million.

What ETF holds Tarsus Pharmaceuticals' stock ?

Invesco Raymond James SB-1 Equity ETF holds 39,637 shares of TARS stock, representing 0.71% of its portfolio.

When did Tarsus Pharmaceuticals IPO?

(TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Who are Tarsus Pharmaceuticals' major shareholders?

Tarsus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.52%), Vivo Capital LLC (5.39%), Vanguard Group Inc. (4.82%), TFG Asset Management GP Ltd (2.42%), Dimensional Fund Advisors LP (1.30%) and Artisan Partners Limited Partnership (1.18%). Insiders that own company stock include Andrew D Goldberg, Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc.
View institutional ownership trends
.

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TARS) was last updated on 2/22/2024 by MarketBeat.com Staff